Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  FIRST NORTH STOCKHOLM  >  Biovica International AB (publ)    BIOVIC B   SE0008613731

BIOVICA INTERNATIONAL AB (PUBL)

(BIOVIC B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Biovica International AB is a Sweden-based biotechnology company. It develops and commercializes blood-based biomarker assays for the monitoring of cancer therapies and for prediction of patient outcome. The Company has focus on breast cancer and its main product DiviTum is a blood-based test, which measures the activity of the enzyme thymidine kinase-1 (TK) in blood serum or cell cultures. The Company collaborates with numerous institutions, such as Karolinska Institutet in Sweden and Dana Farber Cancer Institute, Washington University, Baylor College of Medicine, City of Hope Research & Treatment Center in the Unites States, as well as The International Breast Cancer Study Group (IBCSG) based in Switzerland and Breast International Group in Belgium.

Number of employees : 17 people.
Sales per Business
2020
SEK (in Million)%
Biomarkers1.67100%
Sales per region
2020
SEK (in Million)%
United States1.2574.7%
European Union excluding Sweden0.39723.8%
Asia0.0251.5%
Managers
NameAgeSinceTitle
Anders Rylander492011Chief Executive Officer & Director
Lars Erik Holmqvist612019Chairman
Adam Germunder35-Operations Director
Cecilia Driving482016CFO, Head-Human Resource, IR & EVP
Mattias Bergqvist49-Director-Clinical Development
Otti Bengtsson Gref512020Director-Research & Development
Jarl Ulf Birger Jungnelius, Dr.682014Independent Director
Maria Holmlund632016Independent Director
Jesper Söderqvist, Dr.532013Independent Director
Henrik Osvald602019Independent Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 16,710,238 16,565,848 99.1% 0 0.0% 70.3%
Stock B 0 6,863,134 0 0.0% 0 0.0%
Shareholders
NameEquities%
Coeli Asset Management AB 1,170,082 5.50%
Northern Light Management AB 1,106,437 5.20%
Gunnar Rylander 572,112 2.69%
Henrik Osvald 564,106 2.65%
LYM Consulting AB 493,810 2.32%
Lars Erik Holmqvist 480,630 2.26%
Anders Rylander 379,756 1.79%
Ålandsbanken Fondbolag AB (Sweden) 339,117 1.59%
Eccenovo AB 300,000 1.41%
East Capital Financial Services AB 132,750 0.62%
Company contact information
Biovica International AB
Dag Hammarskjölds väg 54B
Uppsala Science Park
Uppsala 752 37

Phone : +46.18.44.44.830
Fax : +46.18.57.24.28
Web : http://www.biovica.com
Sector Bio Diagnostics & Testing